Oppenheimer Thinks Acasti Pharma’s Stock is Going to Recover

By Ryan Adsit

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Acasti Pharma (ACSTResearch Report), with a price target of $7.00. The company’s shares closed last Monday at $0.47, close to its 52-week low of $0.25.

According to TipRanks.com, Gershell is a 5-star analyst with an average return of 14.2% and a 50.0% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acasti Pharma with a $4.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.08 and a one-year low of $0.25. Currently, Acasti Pharma has an average volume of 2.18M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.